Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (2703)	7/16/1999 5:05:00 PM
From: Makahadan	Respond to of 4140

Okay. I am posting this on SI, Yahoo, RB, and Fool boards. My thanks again to RockDoc, Joe, Skane, Imirish and others who have posted and/or answered my doubts in the face of the short barrage. May this post be my contribution and a tiny bit of reciprocation. I had called Sunrise's VP of Investor Relations, Ed Coghlan, late yesterday and left a message saying I realized they are up against a dramatic week, a Florida meeting, etc. but could he please call me since I was stressing out under the relentless Sturza/Street.com stories. I was pleased that he found the time to call me back. I told him I would not quote him without permission, and requested he let me know what I could repeat, and he was quite open; if anything, I am the one editing things down. This is as close as word to word as I can be, but I remind you it is my version as I couldn't write as fast as we were talking. Mr. Coghlan said that a key thing he'd say regarding the stories is "a person is known by the people he quotes." If I understood correctly, he said the reporter for street.com was NOT at the so-called chalk talk...... Regarding the discrepancies of what the SNRS CEO presented at the talk as purported in the report, Mr. Coghlan said he could only characterize their version of things as "silly, just plain silly." Personally, I (Makahadan ) do not like the investigators holding SNRS. How can that not at least raise a question of conflict of interests? Mr. Coghlan's response was that if one knew these doctors, it would be unimaginable that they would put their reputations on the line. I said that's nice if you know the doctors, but most of us don't. I can only take comfort in knowing that a few of you on the boards whom I've corresponded with do know the docs and speak highly of them. Mr. Coghlan noted, as many of us have, that even the shorts are acknowledging that SNRS will probably pass the FDA. He said "the company is very excited about this unique opportunity to revolutionize the treatment of hyperopia." His key statement as far as I'm concerned was "the reaction we've had at Sunrise to these events is that we believe the information distributed to be false and misleading." Rather than try to recount every last detail of our conversation, I will just say that it was a wonderful counterbalance to the sniping tone of the street.com reports to hear Mr. Coghlan's side of things presented in what I felt was a tone of calm irritation while maintaining a sense of humor, and I was ready to buy options except I'm as extended as I can be and if SNRS does what we longs hope, I won't have to be jealous of anyone......... May whatever Supreme Being or act of randomness shone It's light on the San Antonio Spurs cast similar blessings upon we Sunrise Longs. Aloha...........

To: majormember who wrote (2703)	7/26/1999 3:34:00 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 4140

AS I said, BEAM is the REAL deal: "FDA PANEL RECOMMENDS APPROVAL OF SUMMIT LASER FOR WIDEST RANGES 7/26/99 14:33 of Myopia and Astigmatism With LASIK; Final Approval Pending for State-of-the-Art Technique Business/Technology Editors WALTHAM, Mass.--(BUSINESS WIRE)--July 26, 1999--Summit Technology, Inc. (NASDAQ Symbol:BEAM) announced today that the Food and Drug Administration (FDA) Ophthalmic Advisory Panel on July 23, 1999 recommended approval of the Company's PMA (Pre-Market Approval) application for treatment of high myopia and high astigmatism with LASIK using the Summit Apex Plus Excimer Laser Workstation. The Panel recommended approval of the Summit system for up to 14.0 diopters (D) of nearsightedness as well as an extended astigmatism range of up to 5.0 diopters. Final acceptance of the Panel's recommendation by the FDA would result in Summit having approval to treat the highest range of nearsightedness and astigmatism in the industry. The Panel also recommended that the treatment ranges be made available to persons 18 years of age or older. Summit is currently approved for those older than age 21; this extension would expand the reach of Summit physicians across the country, allowing them to treat more patients. The FDA usually accepts the Panel's recommendations. The Panel also endorsed the LASIK technique for treatment within these expanded ranges. LASIK (laser-assisted in-situ keratomileusis) is a technique that is already being widely practiced by a high percentage of refractive surgeons and is gaining increasing acceptance because of high success rates, minimal patient discomfort and low complication levels. During the procedure, a skilled surgeon uses a special device called a microkeratome to create a thin flap of tissue, about a third of the thickness of the cornea. Next, the laser is applied to resculpt the corneal surface beneath the flap. Finally, the flap is repositioned over the treated area. "We are extremely pleased with the Panel's recommendation. In addition to the LASIK recommendation, the range of treatments available to surgeons using our Apex Plus system will approximately double for myopic patients when approved by the FDA. Every such approval increases our ability to compete and to succeed in the very dynamic and exciting laser vision correction market," said Robert J. Palmisano, Chief Executive Officer of Summit Technology. "We thank the Summit physicians and study coordinators who participated in the clinical trials for their dedication and strong commitment to this effort," he added. The following table depicts the increased ranges that will be available to Summit customers and their patients following final FDA approval. -0- T Currently Upon FDA Approval Myopia 7.0D 14.0D Astigmatism <4.0D 5.0D (with some limitations) Age 21 18 Lower range of treatment 1.0D 0.0D T -0- "The LASIK technique has revolutionized refractive eye surgery," said Dan Durrie, M.D. of Hunkeler Eye Centers, Kansas City, MO, who was a medical monitor of the clinical studies and a presenter on Summit's behalf to the Panel. "This procedure often provides immediate visual results with little or no discomfort, resulting in a high degree of patient satisfaction." Founded in 1985, Summit Technology is a leading developer, manufacturer and marketer of ophthalmic laser systems and related products designed to correct common vision disorders such as nearsightedness, farsightedness and astigmatism. In 1995, Summit was the first excimer laser company to receive FDA approval for its excimer laser system for the correction of mild to moderate myopia in the U.S. Autonomous, a wholly owned subsidiary, is engaged in the design and development of next generation excimer laser instruments for laser refractive surgery. The Company's LADARVision system combines laser radar eye tracking with narrow beam shaping technology. In addition, through its wholly-owned subsidiary, Lens Express, Summit sells contact lenses and related products. Cautionary Statement under "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995: Statements made in this report contain information about the Company's future business prospects. These statements may be considered "forward-looking". These statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. Among these risks and uncertainties are: competition from other manufacturers and vision correction technologies, delays in obtaining regulatory approvals, challenges to patents owned and licensed by the Company affecting per procedure revenues and adverse litigation results. For additional information and risks associated with the Company's business prospects, and future operating results, please refer to Summit's annual report on Form 10-K for the year ended December 31, 1998. --30--dp/bos* CONTACT: Summit Technology, Inc. Kate Sturgis Burnham, (781) 672-0517 kate.burnham@sum-tech.com"